Friday 6 November 2026 Export ZLAB’s income statement to Excel — free account

Zai Lab Limited Unsponsored ADR

Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.

Revenue: −6.79%
EPS: −24.3%
Free cash flow: −95.5%
Total debt: +24.3%

Quarter to September 2026, against a year earlier

25.72 3.12 +13.81%

Follow ZLAB

Alert me

Market cap: $2.6B
P/E: 0.0×
Fwd P/E: −10.0×
Dividend yield: —
F-score: 4/9
Altman Z: −0.24
Beneish M: −2.35
Dividend safety: n/a

Overview

Zai Lab Limited Unsponsored ADR (ZLAB) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Zai Lab Limited Unsponsored ADR (ZLAB) trades at a P/S ratio of 5.7×. Over the past ten years it has ranged from 0.0× (December 2019) to 442× (February 2020); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ZLAB/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Zai Lab Limited Unsponsored ADR P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ZLAB/metrics/ps-ratio">Zai Lab Limited Unsponsored ADR (ZLAB) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	4.2×	(35.35%)
FY2024	6.5×	(31.21%)
FY2023	9.4×	(31.28%)
FY2022	13.7×	(66.07%)
FY2021	40.5×	(77.96%)
FY2020	184×	(37.18%)
FY2019	293×	—
FY2018	0.0×	—

Period	P/S ratio	Change
Sep 2026	6.7×	41.11%
Jun 2026	4.7×	2.72%
Mar 2026	4.6×	9.44%
Dec 2025	4.2×	(50.35%)
27 more quarters	Free account

Against its own ten years

Low 0.0× High 442×

Ten-year median 9.0×

Current reading's percentile 15

Company	P/S ratio
PHVS Pharvaris N.V. compare	n/m
MBX MBX Biosciences, Inc. compare	n/m
ADMA ADMA Biologics Inc compare	5.7×
ZLAB Zai Lab Limited Unsponsored ADR	5.7×
RCUS Arcus Biosciences, Inc. compare	22.8×
XNCR Xencor, Inc. compare	24.8×
RXRX Recursion Pharmaceuticals, Inc. compare	27.9×
NAMS NewAmsterdam Pharma Company N.V. compare	91.1×
CLDX Celldex Therapeutics, Inc. compare	2,498×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Zai Lab Limited Unsponsored ADR (ZLAB) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ZLAB

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ZLAB

Stockrow Weekly